The Alpha Thalassaemia drugs in development market research report provides comprehensive information on the therapeutics under development for Alpha Thalassaemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Alpha Thalassaemia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Alpha Thalassaemia and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Alpha Thalassaemia by seven companies/universities/institutes. The top development phase for Alpha Thalassaemia is phase 0 with two drugs in that stage. The Alpha Thalassaemia pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Alpha Thalassaemia pipeline products market are: Silence Therapeutics, Shanghai Pharmaceuticals and Merck.
The key targets in the Alpha Thalassaemia pipeline products market include Hemoglobin Subunit Alpha (Alpha Globin or Hemoglobin Alpha Chain or HBA1 or HBA2), Growth/Differentiation Factor 11 (Bone Morphogenetic Protein 11 or BMP11 or GDF11), and Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN).
The key mechanisms of action in the Alpha Thalassaemia pipeline product include Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) Inhibitor with one drug in Phase II. The Alpha Thalassaemia pipeline products include four routes of administration with the top ROA being Subcutaneous and four key molecule types in the Alpha Thalassaemia pipeline products market including Gene-Modified Cell Therapy, and Small Molecule.
Alpha Thalassaemia overview
Alpha thalassaemia (or α-thalassaemia) is a group of inherited blood disorders, characterised by a reduced production of the α-globin chains of the haemoglobin molecule, while the β-globin chains are normally produced. This means that there will be an accumulation of the β-(unpaired) globin chains, within the developing red cell. The production of the α-globin chains is regulated by four α-genes, two on each chromosome
For a complete picture of Alpha Thalassaemia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
